NRXS
Neuraxis·AMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 2
Ample Liquidity
High Gross Profit Margin
Low Cash Short-term Debt Ratio
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NRXS
Neuraxis, Inc.
A company that makes devices for children with IBS-related functional abdominal pain
Healthcare Equipment and Supplies
04/17/2012
08/09/2023
American Stock Exchange
21
12-31
Common stock
11611 N. Meridian Street, Suite 330, Carmel, IN 46032
--
Neuraxis, Inc., was founded in 2011 and was incorporated in Indiana on April 17, 2012 as Innovative Health Solutions, Inc. The company is a medical technology company focused on developing neuromodulation therapies to address chronic and debilitating diseases in children and adults. The company is committed to advancing science with proprietary transcutaneous neural electric field stimulation (PENFS) technology developed in-house. The company believes that scientific and evidence-based research excellence is necessary for adoption by the medical and scientific community. Additional clinical trials of PENFS in multiple pediatric conditions are underway with the launch of an FDA indication (functional abdominal pain associated with IBS in adolescents aged 11-18 years).
Earnings Call
Q2/2025
Estimate EPS-0.19
Actual EPS-0.22
Estimate Revenue983.62K
Actual Revenue894.00K
NeurAxis Q2 2025: Unpacking Contradictions in Sales Strategy, Reimbursement, and Revenue Growth
Aug 12,2025 12:39
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
NRXS has released its 2025 Q3 earnings. EPS was reported at -0.24, versus the expected -0.2, missing expectations. The chart below visualizes how NRXS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
NRXS has released its 2025 Q3 earnings report, with revenue of 811.41K, reflecting a YoY change of 21.72%, and net profit of -2.12M, showing a YoY change of -20.94%. The Sankey diagram below clearly presents NRXS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
